EUVIMEDEUVIMED entdecken
Crossref

Influence of UGT2B7, UGT1A4 and ABCG2 Polymorphisms on the Pharmacokinetics and Therapeutic Efficacy of Lamotrigine in Patients with Epilepsy

Jing Yang, Jinxingyi Wang, Lijie Ning, Changsong Wu, Yang Liu, Jie Xia, Yanping Guan, Qian Liu, Jianghuan Zheng

European Journal of Drug Metabolism and Pharmacokinetics · 2024

DOI: 10.1007/s13318-024-00894-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Drug Metabolism and Pharmacokinetics, 2024. Verfasst von Jing Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The Second Affiliated Hospital of Guizhou Medical University, Kaili, 556000, Guizhou, China. Hauptthemen laut MEDLINE: Lamotrigine, Glucuronosyltransferase, ATP Binding Cassette Transporter, Subfamily G, Member 2, Epilepsy. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: the Science and Technology Project of Qiandongnan Prefecture, the Science and Technology Project of Guizhou province, Science and Technology Program of Guizhou Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVES: A substantial inter-individual variability has been observed in the pharmacokinetics of lamotrigine. The aim of the study was to investigate the impact of genetic polymorphism of the metabolizing enzymes (UGT2B7, UGT1A4) and transporter (ABCG2) on the pharmacokinetics and therapeutic efficacy of lamotrigine in patients with epilepsy. METHODS: The genetic analysis of single-nucleotide polymorphisms was conducted using polymerase chain reaction sequence. High-performance liquid chromatography/tandem mass spectrometry was employed to measure the plasma concentrations of lamotrigine. The efficacy of lamotrigine was assessed by evaluating the reduction rate of epileptic seizure frequency. RESULTS: This study included a cohort of 331 patients who were treated with lamotrigine as monotherapy. A linear correlation was observed between the lamotrigine concentration and daily dose taken (r = 0.58, p < 2.2e-16). Statistically significant differences were found in both the median plasma concentration and dose-adjusted concentration (C/D ratio) when comparing the ineffective to the effective group (p < 0.05). Multivariate analysis showed that UGT1A4 rs2011425, ABCG2 rs2231142 polymorphisms and age had a significant relationship with the lamotrigine concentrations (p < 0.05). Age was a predictive factor for C/D ratio (p < 0.001). Lamotrigine concentration and weight were good predictive factors for effective seizure outcomes (odds ratio [OR] = 0.715, 95% CI 0.658-0.776, p < 0.001; OR = 0.926, 95% CI 0.901-0.951, p < 0.001, respectively). The cut-off values of lamotrigine trough concentrations for clinical outcomes in the age-related groups were determined as 2.49 μg/ml (area under the receiver-operating characteristic curve [AUC]: 0.828, 95% CI 0.690-0.966), 2.70 μg/ml (AUC: 0.805, 95% CI 0.745-0.866) and 3.25 μg/ml (AUC: 0.807, 95% CI 0.686-0.928) for the adult group, adolescent group, and toddler and school-age group, respectively. CONCLUSIONS: UGT1A4 rs2011425 and ABCG2 rs2231142 were correlated with lamotrigine concentrations. Lower lamotrigine trough concentration was found in the ineffective group and the troughs were associated with seizure outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LamotrigineGlucuronosyltransferaseATP Binding Cassette Transporter, Subfamily G, Member 2EpilepsyAnticonvulsantsPolymorphism, Single NucleotideNeoplasm ProteinsHumansMaleFemaleAdultMiddle AgedYoung AdultAdolescentAgedChildTreatment OutcomeCohort Studies

Substanzen

LamotrigineGlucuronosyltransferaseATP Binding Cassette Transporter, Subfamily G, Member 2bilirubin glucuronoside glucuronosyltransferaseAnticonvulsantsABCG2 protein, humanUGT2B7 protein, humanNeoplasm Proteins

Autor:innen und Institutionen

  • Department of Neurology, The Second Affiliated Hospital of Guizhou Medical University, Kaili, 556000, Guizhou, China.
  • Department of Pharmacy, The Second Affiliated Hospital of Guizhou Medical University, Kaili, 556000, Guizhou, China.
  • Institute of Clinical Pharmacology, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, 510006, China. guanyp3@mail2.sysu.edu.cn.
  • Department of Pharmacy, The Second Affiliated Hospital of Guizhou Medical University, Kaili, 556000, Guizhou, China. qian159158@163.com.
  • Department of Neurology, The Second Affiliated Hospital of Guizhou Medical University, Kaili, 556000, Guizhou, China. 1418528797@qq.com.

Förderung

  • the Science and Technology Project of Qiandongnan Prefecture
  • the Science and Technology Project of Guizhou province
  • Science and Technology Program of Guizhou Province

Zitieren

APA

Yang, J., Wang, J., Ning, L., Wu, C., Liu, Y., Xia, J., Guan, Y., Liu, Q., & Zheng, J. (2024). Influence of UGT2B7, UGT1A4 and ABCG2 Polymorphisms on the Pharmacokinetics and Therapeutic Efficacy of Lamotrigine in Patients with Epilepsy. European Journal of Drug Metabolism and Pharmacokinetics. https://doi.org/10.1007/s13318-024-00894-4

Vancouver

Yang J, Wang J, Ning L, Wu C, Liu Y, Xia J, et al. Influence of UGT2B7, UGT1A4 and ABCG2 Polymorphisms on the Pharmacokinetics and Therapeutic Efficacy of Lamotrigine in Patients with Epilepsy. European Journal of Drug Metabolism and Pharmacokinetics. 2024. doi:10.1007/s13318-024-00894-4

BibTeX
@article{Yang2024,
  author = {Yang, Jing and Wang, Jinxingyi and Ning, Lijie and Wu, Changsong and Liu, Yang and Xia, Jie and Guan, Yanping and Liu, Qian and Zheng, Jianghuan},
  title = {Influence of UGT2B7, UGT1A4 and ABCG2 Polymorphisms on the Pharmacokinetics and Therapeutic Efficacy of Lamotrigine in Patients with Epilepsy},
  journal = {European Journal of Drug Metabolism and Pharmacokinetics},
  year = {2024},
  doi = {10.1007/s13318-024-00894-4}
}
Kostenlos starten →